Bank of America Corp DE Boosts Holdings in Henry Schein, Inc. $HSIC

Key Points

• Bank of America increased its Henry Schein stake by 5.9% in the first quarter, bringing its holdings to 1.22 million shares worth approximately $90 million. Institutional investors collectively own 96.62% of HSIC.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $92.27. Price targets range from $82 to $112, including a higher $112 target from Citigroup.
• Henry Schein exceeded quarterly expectations, reporting $1.27 in EPS and $3.46 billion in revenue, with revenue up 6.7% year over year. The company issued fiscal 2026 EPS guidance of $5.29 to $5.39.

Bank of America Corp DE boosted its stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 5.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,221,585 shares of the company's stock after acquiring an additional 68,593 shares during the period. Bank of America Corp DE owned 1.07% of Henry Schein worth $90,031,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HSIC. Ameriprise Financial Inc. increased its stake in shares of Henry Schein by 3,275.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company's stock worth $165,594,000 after purchasing an additional 2,199,695 shares during the last quarter. Bank of Montreal Can lifted its stake in Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company's stock valued at $162,102,000 after purchasing an additional 2,087,666 shares during the last quarter. Norges Bank purchased a new position in Henry Schein in the fourth quarter valued at approximately $88,116,000. Southpoint Capital Advisors LP grew its holdings in Henry Schein by 28.0% during the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company's stock valued at $235,840,000 after purchasing an additional 700,000 shares during the period. Finally, Staley Capital Advisers Inc. grew its holdings in Henry Schein by 12,115.2% during the first quarter. Staley Capital Advisers Inc. now owns 450,740 shares of the company's stock valued at $33,220,000 after purchasing an additional 447,050 shares during the period. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on HSIC shares. Robert W. Baird set a $97.00 target price on Henry Schein in a research note on Wednesday, May 6th. Stifel Nicolaus set a $95.00 price target on Henry Schein in a research note on Wednesday. UBS Group set a $94.00 price objective on Henry Schein and gave the stock a "neutral" rating in a report on Wednesday. Mizuho lowered their price objective on Henry Schein from $88.00 to $82.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 6th. Finally, Citigroup restated a "buy" rating and issued a $112.00 price objective (up from $100.00) on shares of Henry Schein in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $92.27.

Insiders Place Their Bets

In related news, Director William K. Daniel purchased 10,000 shares of the firm's stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the transaction, the director directly owned 20,000 shares in the company, valued at approximately $1,383,800. This represents a 100.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.89% of the stock is owned by insiders.

Henry Schein Trading Down 0.1%

NASDAQ:HSIC opened at $88.13 on Friday. Henry Schein, Inc. has a 1 year low of $61.94 and a 1 year high of $92.18. The stock's fifty day moving average price is $83.49 and its two-hundred day moving average price is $78.67. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.32 and a quick ratio of 0.75. The company has a market cap of $9.82 billion, a P/E ratio of 25.69, a P/E/G ratio of 1.68 and a beta of 0.80.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.24 by $0.03. The company had revenue of $3.46 billion for the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The firm's revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.10 EPS. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, analysts expect that Henry Schein, Inc. will post 5.35 EPS for the current year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source